Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.77 |
| ▸ | CNR2 | P34972 | 7/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3562619 | 0.88 | CNR1 (0.76) | CNR1CNR2CA1CA2ALDH1A1 | |
| SCHEMBL1022761 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL1025584 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL1023263 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL16340252 | 0.87 | CNR1 (0.65) | CNR1CNR2CA1CA2ALDH1A1 | |
| SCHEMBL4306103 | 0.85 | CNR1 (0.83) | CNR1CNR2ALDH1A1LMNA | |
| SCHEMBL4304848 | 0.82 | CNR1 (0.90) | CNR1CNR2 | |
| SCHEMBL1022762 | 0.81 | CNR1 (0.75) | CNR1CNR2 | |
| SCHEMBL12794072 | 0.81 | CNR1 (0.75) | CNR1CNR2 | |
| SCHEMBL1025583 | 0.81 | CNR1 (0.75) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053983-A1 | (5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2011-03-03 | — | — | US | disclosed |
| EP-2274298-A1 | (5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | Abbott Healthcare Products B.V. (NL) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009130234-A1 | (5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053983-A1 | (5R)-1,5-DIARYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDINE DERIVATIVES HAVING CB1-ANTAGONISTIC ACTIVITY | CNR1, CNR2, HTR5A | CNR1 1/4885CNR2 2/4885CA1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.